Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
about
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyFinal results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancerOptimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXFilling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/00Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialA multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 studyAdjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trialPrognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic reviewIs risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 TrialA network-based phenotype mapping approach to identify genes that modulate drug response phenotypes.ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumoursThe association between adiposity and breast cancer recurrence and survival: A review of the recent literatureInterdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.CMF revisited in the 21st century.Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis.Chemotherapy regimens in early breast cancer: major controversies and future outlook.The role of anthracyclines in the treatment of early breast cancer.The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise.CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data.Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients.Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016.Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial†Lessons learned from development of docetaxel
P2860
Q26853619-80591C8C-61AB-4E63-8B0E-8D704C53DB22Q27011658-8DD34D4D-94F3-484E-9E89-42192669EC22Q33659628-5F2AC431-9A7D-4699-8AAC-AD6222466141Q33698446-D25E4083-F994-4539-89EC-1A88103C3C8DQ33739357-4B1B4D42-E9DB-48CA-8088-36DE4200620FQ33785011-AD74E127-0336-49FC-BB8E-724E04761BF6Q34199348-F0F2048E-56B4-41C6-BD08-49811752CC44Q34379034-6FAF96D6-91AB-4630-810A-D4FA28DA1CD5Q35889568-21134476-16F4-4AE9-8B72-BEAF6F577363Q35994850-5CBAEC11-10A3-4D4C-9D4E-647CABF312B8Q36055133-79FEC7CE-F182-40F8-B77B-A81206F0E353Q36102798-989CB6B1-ECEB-4503-AB4A-A431A2CA7F85Q36245341-A91D28AF-D778-49CD-9521-92575A43ACE3Q37107396-C6291B35-440A-4D97-B59A-A53909F2B198Q37206289-2717F10A-1004-4CDF-94CE-7062136E5F9FQ37208730-E2DA5CF1-54B4-448C-AF2C-AA936E727B2CQ37309845-11B3D7FD-2D04-4BE3-A447-3D1ECA2A7B90Q37321804-C4D9F3E8-6EC6-4486-A118-AE26690B881CQ37411962-CA45E77C-C719-4ED6-AD9C-6F9FC9048772Q37452750-7C1344D2-5208-47A9-A182-8C2518626D99Q37579337-8122A25F-0BD0-4594-9CD3-EC04AFA4F731Q37657782-442FE509-2882-483C-85F9-4C12CA410EC8Q37895805-D6825A2C-C1C3-4644-A02D-5722379C6F29Q37903140-EC27C96E-5041-489B-B13E-EEBDC43820BBQ38017967-DC921126-9885-4E07-A18A-224CBEFC7F0DQ38081243-1BAC0160-BCC5-43F4-9BE1-AB23474E77E4Q38207452-5F16E346-2E13-4B63-AF4D-3FC862693806Q38426636-62CF6400-03BE-4FCA-B5A8-057F005F7E55Q38652510-CE0AF9BD-8A09-43F5-B6E5-0F956591061AQ38823649-CF4094CA-0B76-4E77-948C-95EC9D3C0620Q39719978-90EBA10C-9611-4B9A-8173-08374C6C441BQ40294108-F2E1CC79-A41A-4B27-8701-6C498293450DQ40987023-6CA0C3BD-28B1-48C9-96EC-74807B62A313Q42113569-5C7855BD-EC81-45D9-A592-A012195EBFFFQ42470916-5C5988A2-A27A-429A-ABA5-8D8691253E50Q42486311-E726A791-16FD-49F2-9C9B-9C8D1E71931DQ47372732-9EE6C23C-C592-485C-8976-51E48C2FA953Q51040724-0D95E411-FDE1-4D9F-A79C-9E21053B804BQ57265716-37DE7D0C-8C14-4C2A-AD60-DD4BDF5C5CD1Q58382477-14AB568F-1E45-4926-B649-6CD504A602A8
P2860
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Adjuvant chemotherapy with seq ...... Group 02-98 randomized trial.
@en
Adjuvant chemotherapy with seq ...... Group 02-98 randomized trial.
@nl
type
label
Adjuvant chemotherapy with seq ...... Group 02-98 randomized trial.
@en
Adjuvant chemotherapy with seq ...... Group 02-98 randomized trial.
@nl
prefLabel
Adjuvant chemotherapy with seq ...... Group 02-98 randomized trial.
@en
Adjuvant chemotherapy with seq ...... Group 02-98 randomized trial.
@nl
P2093
P2860
P356
P1476
Adjuvant chemotherapy with seq ...... l Group 02-98 randomized trial
@en
P2093
Aron Goldhirsch
BIG 02-98 Collaborative Group
Belguendouz Bendahmane
Bo Nordenskjöld
Daniel Vorobiof
Guy van Hazel
Istvan Lang
John Crown
Jorge Gutiérrez
P2860
P304
P356
10.1093/JNCI/DJM287
P407
P577
2008-01-08T00:00:00Z